Profile | GDS2987 / GI_20143945-I |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 13 | 42 |
GSM215244 | HMVEC_vehicle_rep2 | 19.8 | 45 |
GSM215253 | HMVEC_vehicle_rep3 | ||
GSM215254 | HMVEC_atorvastatin_rep1 | 17.7 | 43 |
GSM215282 | HMVEC_atorvastatin_rep3 | 33.7 | 59 |
GSM215344 | HMVEC_atorvastatin_rep2 | 6.2 | 16 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 35.3 | 55 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 25.3 | 45 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 38.9 | 53 |
GSM215294 | HMVEC_SLx2119_rep1 | 10.8 | 37 |
GSM215295 | HMVEC_SLx2119_rep2 | 33.1 | 54 |
GSM215296 | HMVEC_SLx2119_rep3 | 41.8 | 56 |
GSM215297 | PASMC_vehicle_rep1 | 35.8 | 48 |
GSM215298 | PASMC_vehicle_rep2 | ||
GSM215310 | PASMC_vehicle_rep3 | 37.6 | 51 |
GSM215311 | PASMC_atorvastatin_rep1 | 19.2 | 33 |
GSM215312 | PASMC_atorvastatin_rep2 | 28.7 | 42 |
GSM215313 | PASMC_atorvastatin_rep3 | 52.4 | 60 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 8.4 | 14 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 21.3 | 39 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 18 | 30 |
GSM215327 | PASMC_SLx2119_rep1 | 33.4 | 50 |
GSM215328 | PASMC_SLx2119_rep2 | 15.5 | 28 |
GSM215329 | PASMC_SLx2119_rep3 | 13.3 | 26 |
GSM215330 | Fibroblasts_vehicle_rep1 | 26.4 | 51 |
GSM215331 | Fibroblasts_vehicle_rep2 | 26.7 | 56 |
GSM215332 | Fibroblasts_vehicle_rep3 | 8.6 | 29 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 23.2 | 51 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 13.3 | 35 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | 32.5 | 58 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | ||
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | ||
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 7.8 | 22 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 28.7 | 60 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 12.3 | 33 |
GSM215341 | Fibroblasts_SLx2119_rep3 | 25.3 | 52 |